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The fields of synthetic biology and microbiome research developed greatly over the last decade. The 
convergence of those two disciplines is now enabling the development of new therapeutic strategies, using 
engineered microbes that operate from within the gut as living medicines. Inborn errors of metabolism represent 
candidate diseases for these therapeutics, particularly those disorders where a toxic metabolite causing a 
syndrome is also present in the intestinal lumen.  Phenylketonuria (PKU), a rare inherited disease caused by a 
defect in phenylalanine hydroxylase (PAH) activity, is one such disease and is characterized by the 
accumulation of systemic phenylalanine (Phe) that can lead to severe neurological deficits unless patients are 
placed on a strict low-Phe diet. As an alternative treatment, Escherichia coli Nissle (EcN), a well-characterized 
probiotic, was genetically modified to efficiently import and degrade Phe (SYN-PKU). The coupled expression of 
a Phe transporter with a Phe ammonia lyase (PAL) allows rapid conversion of Phe into trans-cinnamic acid 
(TCA) in vitro, which is then further metabolized by the host to hippuric acid (HA) and excreted in the urine. 
Experiments conducted in the enu2-/- PKU mouse model showed that the oral administration of SYN-PKU is 
able to significantly reduce blood Phe levels triggered by subcutaneous Phe injection. Decreases in circulating 
Phe levels were associated with proportional increases in urinary HA, confirming that Phe metabolism was 
caused by the engineered pathway in SYN-PKU.  Subsequent studies have shown that SYN-PKU is similarly 
operative in a non-human primate model, providing a translational link to inform future human clinical studies. In 
addition to SYN-PKU, a second EcN strain was genetically engineered to rapidly import and degrade branched-
chain amino acids (BCAAs) for the treatment of maple syrup urine disease (SYN-MSUD). MSUD, similar to 
PKU, is a rare genetic disorder caused by a defect in branched-chain ketoacid dehydrogenase activity leading to 
the toxic accumulation of BCAAs, particularly leucine, and their ketoacid derivatives. The controlled expression 
in SYN-MSUD of two BCAA transporters, a leucine dehydrogenase, a ketoacid decarboxylase and an alcohol 
dehydrogenase, result in the efficient degradation of BCAAs into branched-chain alcohols. In a mouse model of 
MSUD, the oral delivery of SYN-MSUD suppressed the increase in blood BCAAs level induced by a high-protein 
challenge and prevented the associated moribund phenotype, as measured by locomotor activity. In conclusion, 
the therapeutic effects observed with SYN-PKU and SYN-MSUD in pre-clinical studies support the further 
evaluation of engineered microbes as promising approaches for serious inborn errors of metabolism. 
 
 
